Healios K.K. (OTCMKTS:HLOSF) Short Interest Down 33.9% in March

Healios K.K. (OTCMKTS:HLOSF) was the target of a significant decline in short interest in March. As of March 13th, there was short interest totaling 502,899 shares, a decline of 33.9% from the February 26th total of 761,032 shares. Based on an average trading volume of 80 shares, the short-interest ratio is presently 6,286.2 days.

Healios K.K. Stock Performance

HLOSF stock remained flat at $2.70 on Monday. The company has a 50 day simple moving average of $2.29 and a two-hundred day simple moving average of $2.84. Healios K.K. has a fifty-two week low of $1.90 and a fifty-two week high of $4.45.

About Healios K.K.

Healios K.K. is a Tokyo–based biotechnology company focused on the development and commercialization of regenerative medicine products and services. The company’s core expertise lies in induced pluripotent stem cell (iPSC)–derived therapies, with a pipeline that includes retinal pigment epithelium (RPE) cells for age‐related macular degeneration and neural cell products targeting neurological disorders. Healios operates a specialized cell processing center in Chuo‐ku, Tokyo, adhering to stringent quality standards for clinical‐grade cell manufacturing.

Beyond its proprietary programs, Healios provides contract development and manufacturing services (CDMO) to pharmaceutical and research institutions.